Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
plerixafor/low-dose tacrolimus (MRG-001) / MedRegen
NCT04646603: MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients	Recruiting	2a	40	US	MRG-001, Placebo	MedRegen LLC, ICON plc, Johns Hopkins University	COVID-19, ARDS, Human, Stem Cells, Regeneration	03/22	07/22
NCT05844527: Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients	Recruiting	2	10	US	MRG-001, Saline	MedRegen LLC	Wound of Skin, Abdominal Wound	10/24	10/24
NCT06307522: MRG-001 in Patients With Alcoholic Hepatitis	Not yet recruiting	2	32	NA	MRG-001	MedRegen LLC	Alcoholic Hepatitis, Acute Alcoholic Hepatitis	09/26	12/26
SUMMIT, NCT06308926: MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients	Not yet recruiting	2	60	NA	MRG-001 (Low-dose), MRG-001 (High-dose), Placebo	MedRegen LLC, Vanderbilt University Medical Center	Acute Respiratory Distress Syndrome, Respiratory Failure, Respiratory Distress Syndrome, Respiratory Tract Diseases, Cytokine Storm	02/26	07/26
NCT06315608: MRG-001 in Patients With Amyotrophic Lateral Sclerosis	Not yet recruiting	2	10	NA	MRG-001	MedRegen LLC	Amyotrophic Lateral Sclerosis, Lou Gehrig Disease, Motor Neuron Disease, Motor Neuron Atrophy	01/26	03/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
plerixafor/low-dose tacrolimus (MRG-001) / MedRegen
NCT04646603: MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients	Recruiting	2a	40	US	MRG-001, Placebo	MedRegen LLC, ICON plc, Johns Hopkins University	COVID-19, ARDS, Human, Stem Cells, Regeneration	03/22	07/22
NCT05844527: Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients	Recruiting	2	10	US	MRG-001, Saline	MedRegen LLC	Wound of Skin, Abdominal Wound	10/24	10/24
NCT06307522: MRG-001 in Patients With Alcoholic Hepatitis	Not yet recruiting	2	32	NA	MRG-001	MedRegen LLC	Alcoholic Hepatitis, Acute Alcoholic Hepatitis	09/26	12/26
SUMMIT, NCT06308926: MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients	Not yet recruiting	2	60	NA	MRG-001 (Low-dose), MRG-001 (High-dose), Placebo	MedRegen LLC, Vanderbilt University Medical Center	Acute Respiratory Distress Syndrome, Respiratory Failure, Respiratory Distress Syndrome, Respiratory Tract Diseases, Cytokine Storm	02/26	07/26
NCT06315608: MRG-001 in Patients With Amyotrophic Lateral Sclerosis	Not yet recruiting	2	10	NA	MRG-001	MedRegen LLC	Amyotrophic Lateral Sclerosis, Lou Gehrig Disease, Motor Neuron Disease, Motor Neuron Atrophy	01/26	03/26